

## Appendix 1 - Description of Board Candidates



### **Anders Härfstrand**

Chairman of the Board since 2022

**Education:** Medical Doctor (M.D.) and Doctor of Medical Science (Ph.D.), Karolinska Institute, Stockholm.

**About:** Anders Härfstrand is non-Executive Director at Prothena Corporation (PRTA) and former Executive in e.g. Pharmacia, Pfizer and Serono Pharmaceuticals. Anders has 35 years of experience and a sustained successful global track record within the global pharmaceutical and biotechnology businesses. He has been CEO of smaller biotech businesses. Anders' experience includes significant Board experience in private and publicly listed companies.

**Other ongoing assignments:** Chairman and fully owner of Härfstrand Consulting AG, Non-Executive Director of Prothena Corporation.



### **Johan Luthman**

Member of the Board since 2022

**Education:** Dental (DDS) and medical studies, PhD in Neurobiology and Histology, Karolinska Institute, Stockholm.

**About:** Johan Luthman is EVP & Head of R&D at Lundbeck. He has over 30 years' experience of pharmaceutical industry research and development in neuroscience and immunology. He has previously worked in Eisai Inc., Merck Inc., GeNeuro SA, Serono SA and AstraZeneca AB. Johan has throughout his career been engaged in Alzheimer's disease R&D and he can be viewed among the world's leading experts on the disease. He has led several large therapeutics and diagnostics development programs for Alzheimer's, e.g. the recently FDA-approved drug lecanemab, while at Eisai.

**Other ongoing assignments:** EVP & Head of R&D, H. Lundbeck A/S Denmark



### **Betül Susamis Unaran**

Member of the Board since 2022

**Education:** BS in Industrial Engineering, Bogazici University, Istanbul, MBA, INSEAD, Fontainebleau.

**About:** Betül Susamis Unaran is also member of the Board

of Directors of Ypsomed and dss+ (Dupont Sustainable

Solutions), and Advisory Board Member of Lumanity (an

Arsenal Capital partners' company). She is the Chief

Commercial Officer and Member of the Executive Leadership Team of Unilabs. Her latest roles were

Chief Strategy and Digital Officer at the Zur Rose

Group, Chief Digital Officer at Novartis

Pharmaceuticals and Ferring Pharmaceuticals, and

she has led numerous pharma-digital

therapeutics business development and

transformation efforts. Betül has 20 years'

experience as a highly accomplished leader of

building successful businesses and strong teams.

**Other ongoing assignments:** Member of the Board of Directors of Ypsomed, dss+, and Advisory Board Member of Lumanity. Chief Commercial Officer (CCO) and Member of the Executive Leadership Team at Unilabs.